1-3 of 3
Richard MacLeod
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mavorixafor for Patients with Chronic Neutropenic Disorders: Results from a Phase 1b, Open-Label, Multicenter Study

Julia T. Warren, Kelly J. Walkovich, Audrey Anna Bolyard, Kathryn E. Dickerson, Jolan E. Walter, Diego Cadavid, Eloisa Chapa, Kelly Chen, Richard MacLeod, Katie Peters, Richard Polisson, David C. Dale
Journal: Blood
Blood (2022) 140 (Supplement 1): 1408–1410.
https://doi.org/10.1182/blood-2022-156216
Published: 2022
Journal Articles

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

David C. Dale, Laia Alsina, Antoine Azar, Raffaele Badolato, Ashish Bhandari, Andrea Belschner, Yves Bertrand, Diego Cadavid, Kathryn E. Dickerson, Navid Ezra, Henrik Hasle, Harold Hoffman, Honghua Jiang, Hyoung Jin Kang, Sorena Kiani-Alikhan, Taco W. Kuijpers, Aleksandr D. Kulagin, Daman Langguth, Carina Levin, Richard MacLeod, Olaf Neth, Jane Peake, Yulia Rodina, Anjali Sharathkumar, Anna Shcherbina, Weihua Tang, Matthias G. Vossen, Jean Donadieu
Journal: Blood
Blood (2021) 138 (Supplement 1): 4310.
https://doi.org/10.1182/blood-2021-153346
Published: 2021
Journal Articles

Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

David C. Dale, Frank Caleb Firkin, Audrey Anna Bolyard, Weihua Tang, Honghua Jiang, Richard MacLeod, Diego Cadavid, Yanping Hu
Journal: Blood
Blood (2021) 138 (Supplement 1): 1121.
https://doi.org/10.1182/blood-2021-145759
Published: 2021